SCHEMBL1392166

SCHEMBL1392166

Cc1nc2ccc(Nc3nc(NCc4ccco4)nc(Nc4ccc5nc(C)sc5c4)n3)cc2s1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.64
▸ KCNH3 Q9ULD8 3/20 0.56
▸ MAPT P10636 8/20 0.52
▸ ALDH1A1 P00352 5/20 0.52
▸ MAPK1 P28482 4/20 0.52
▸ NPC1 O15118 3/20 0.52
▸ RAB9A P51151 2/20 0.52
▸ KMT2A Q03164 8/20 0.51
▸ RECQL P46063 2/20 0.51
▸ EGFR P00533 1/20 0.51
▸ SOS1 Q07889 1/20 0.49
▸ KDM4E B2RXH2 4/20 0.49
▸ MEN1 O00255 4/20 0.49
▸ SMN1; SMN2 Q16637 4/20 0.48
▸ LMNA P02545 3/20 0.48
▸ NPSR1 Q6W5P4 2/20 0.48
▸ USP2 O75604 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ NR2F2 P24468 1/20 0.48
▸ XBP1 P17861 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1390978 0.96 TSHR (0.59) TSHRKCNH3MAPTALDH1A1MAPK1
SCHEMBL1390992 0.95 MAPK1 (0.61) TSHRKCNH3MAPTALDH1A1MAPK1
SCHEMBL3107767 0.95 TSHR (0.58) TSHRKCNH3MAPTALDH1A1MAPK1
SCHEMBL1391174 0.94 KMT2A (0.62) TSHRKCNH3MAPTALDH1A1MAPK1
SCHEMBL1390767 0.91 MAPT (0.63) TSHRKCNH3MAPTALDH1A1MAPK1
SCHEMBL1391224 0.91 TSHR (0.55) TSHRKCNH3MAPTALDH1A1MAPK1
SCHEMBL1392051 0.86 TSHR (0.50) TSHRKCNH3MAPTALDH1A1MAPK1
SCHEMBL1392162 0.83 MAPT (0.63) TSHRKCNH3MAPTALDH1A1MAPK1
SCHEMBL6729004 0.76 MAPT (0.53) TSHRKCNH3MAPTALDH1A1MAPK1
SCHEMBL1390995 0.76 MAPT (0.57) TSHRMAPTALDH1A1MAPK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 — — US disclosed
EP-2231624-A2 TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF Progenics Pharmaceuticals, Inc. (US) 2010-09-29 — — EP disclosed
WO-2009091388-A2 TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF PROGENICS PHARMACEUTICALS, INC. (US) 2009-07-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof HAVCR2, ZC3HAV1, MAVS TSHR 3492/4885KCNH3 3535/4885MAPT 3654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback